The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Boehringer Ingelheim and BiomX Collaborate to Discover IBD Microbiome Biomarkers
Finance

Boehringer Ingelheim and BiomX Collaborate to Discover IBD Microbiome Biomarkers

JUL 5, 2022
4D pharma Receives Notice of Delisting From Nasdaq
Finance

4D pharma Receives Notice of Delisting From Nasdaq

JUN 29, 2022
Vedanta Unveils State-of-the-Art Manufacturing Facility
Finance

Vedanta Unveils State-of-the-Art Manufacturing Facility

JUN 29, 2022
Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
Editor's Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview

JUN 27, 2022
4D Pharma Update on Suspension of Trading in the Company’s ordinary shares
Finance

4D Pharma Update on Suspension of Trading in the Company’s ordinary shares

JUN 24, 2022
Bacthera: Enabling the Live Biotherapeutic Industry
Pharma & Human Health

Bacthera: Enabling the Live Biotherapeutic Industry

JUN 20, 2022
Unprecedented case series advances promise of phage therapy
Pharma & Human Health

Unprecedented case series advances promise of phage therapy

JUN 16, 2022
Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection
Infectious Disease & AMR

Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection

JUN 8, 2022
Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages
Infectious Disease & AMR

Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages

JUN 6, 2022
Ethical challenges in microbiome research
Pharma & Human Health

Ethical challenges in microbiome research

MAY 24, 2022
Phage therapy: A model to predict its efficacy against pathogenic bacteria
Infectious Disease & AMR

Phage therapy: A model to predict its efficacy against pathogenic bacteria

MAY 23, 2022